Published June 5, 2026 | Version v1
Journal article Open

A Case of Herpes Zoster Complicated by Herpetic Iridocyclitis and Ramsay-Hunt Syndrome in a Patient with Severe Vitiligo Undergoing Upadacitinib Treatment

Authors/Creators

Files

Figure 1.JPG

Files (1.7 MB)

Name Size Download all
md5:3596ef275cd79bdebca479d93e0df016
1.6 MB Preview Download
md5:67d8a18f0b6141f6e326758a3e0e183f
114.8 kB Preview Download
md5:11bdd058ecb5e234b63397090f117362
20.4 kB Download

Additional details

References

  • 1. Lin B, Chung C, Weng T, Tsai C, Liu S, Chien W, vd. Elevated Risk of Herpes Zoster in Vitiligo Patients: A Nationwide Population‐Based Cohort Study of Taiwan. J Dermatol. Nisan 2026;53(4):596-604.
  • 2. Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, vd. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. Temmuz 2015;3(4):109-20.
  • 3. Chikhoune L, Poggi C, Moreau J, Dubucquoi S, Hachulla E, Collet A, vd. JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases. Rev Médecine Interne. Şubat 2025;46(2):89-106.
  • 4. Ireland PA, Verheyden M, Jansson N, Sebaratnam D, Sullivan J. Infection risk with JAK inhibitors in dermatoses: a meta‐analysis. Int J Dermatol. Ocak 2025;64(1):24-36.